INTRODUCTION: Access to antiretroviral treatment (ART) has expanded dramatically in resource-limited settings. Evaluating loss to follow-up from HIV testing through post-ART care can help identify obstacles to care. METHODS: Routine data were analyzed for adults receiving services in 2 public HIV care systems in central Mozambique. The proportion of people passing through the following steps was determined: (1) HIV testing, (2) enrollment at an ART clinic, (3) CD4 testing, (4) starting ART if eligible, and (5) adhering to ART. RESULTS: During the 12-month study period (2004-2005), an estimated 23,430 adults were tested for HIV and 7005 (29.9%) were HIV positive. Only 3956 (56.5%) of those HIV positive enrolled at an ART clinic < or =30 days after testing. CD4 testing was obtained in 77.1% < or =30 days of enrollment. Of 1506 eligible for ART, 471 (31.3%) started ART < or =90 days after CD4 testing. Of 382 with > or =180 days of potential follow-up time on ART, 317 (83.0%) had pharmacy-based adherence rates > or =90%. DISCUSSION: Substantial drop-offs were observed for each step between HIV testing and treatment but were highest for referral from HIV testing to treatment sites and for starting ART. Interventions are needed to improve follow-up and ensure that people benefit from available HIV services.
INTRODUCTION: Access to antiretroviral treatment (ART) has expanded dramatically in resource-limited settings. Evaluating loss to follow-up from HIV testing through post-ART care can help identify obstacles to care. METHODS: Routine data were analyzed for adults receiving services in 2 public HIV care systems in central Mozambique. The proportion of people passing through the following steps was determined: (1) HIV testing, (2) enrollment at an ART clinic, (3) CD4 testing, (4) starting ART if eligible, and (5) adhering to ART. RESULTS: During the 12-month study period (2004-2005), an estimated 23,430 adults were tested for HIV and 7005 (29.9%) were HIV positive. Only 3956 (56.5%) of those HIV positive enrolled at an ART clinic < or =30 days after testing. CD4 testing was obtained in 77.1% < or =30 days of enrollment. Of 1506 eligible for ART, 471 (31.3%) started ART < or =90 days after CD4 testing. Of 382 with > or =180 days of potential follow-up time on ART, 317 (83.0%) had pharmacy-based adherence rates > or =90%. DISCUSSION: Substantial drop-offs were observed for each step between HIV testing and treatment but were highest for referral from HIV testing to treatment sites and for starting ART. Interventions are needed to improve follow-up and ensure that people benefit from available HIV services.
Authors: W E Cunningham; R M Andersen; M H Katz; M D Stein; B J Turner; S Crystal; S Zierler; K Kuromiya; S C Morton; P St Clair; S A Bozzette; M F Shapiro Journal: Med Care Date: 1999-12 Impact factor: 2.983
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: R Andersen; S Bozzette; M Shapiro; P St Clair; S Morton; S Crystal; D Goldman; N Wenger; A Gifford; A Leibowitz; S Asch; S Berry; T Nakazono; K Heslin; W Cunningham Journal: Health Serv Res Date: 2000-06 Impact factor: 3.402
Authors: J Dennis Fortenberry; Mary McFarlane; Amy Bleakley; Sheana Bull; Martin Fishbein; Diane M Grimley; C Kevin Malotte; Bradley P Stoner Journal: Am J Public Health Date: 2002-03 Impact factor: 9.308
Authors: Anjuli D Wagner; Sarah Gimbel; Kristjana H Ásbjörnsdóttir; Peter Cherutich; Joana Coutinho; Jonny Crocker; Emilia Cruz; Fatima Cuembelo; Vasco Cumbe; McKenna Eastment; Jennifer Einberg; Florencia Floriano; Douglas Gaitho; Brandon L Guthrie; Grace John-Stewart; Alex H Kral; Barrot H Lambdin; Shan Liu; Martin Maina; Nelia Manaca; Mika Matsuzaki; Loris Mattox; Nancy Mburu; R Scott McClelland; Mark A Micek; Ana Olga Mocumbi; Alberto Muanido; Ruth Nduati; Irene N Njuguna; Geoffrey Oluoch; Laura B Oyiengo; Keshet Ronen; Caroline Soi; Bradley H Wagenaar; George Wanje; Lynn D Wenger; Kenneth Sherr Journal: J Acquir Immune Defic Syndr Date: 2019-12 Impact factor: 3.731
Authors: Sarah E Gerdts; Bradley H Wagenaar; Mark A Micek; Carey Farquhar; Marina Kariaganis; Juvenal Amos; Sarah Gimbel; James Pfeiffer; Stephen Gloyd; Kenneth Sherr Journal: J Acquir Immune Defic Syndr Date: 2014-06-01 Impact factor: 3.731
Authors: Elvin H Geng; Mwebesa B Bwana; Winnie Muyindike; David V Glidden; David R Bangsberg; Torsten B Neilands; Ingrid Bernheimer; Nicolas Musinguzi; Constantin T Yiannoutsos; Jeffrey N Martin Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731